tetano
Editor, Senior Moderator
Introduction
This document summarizes recommendations for the use of influenza vaccines approved on February 21, 2013 by the Advisory Committee on Immunization Practices (ACIP). An expanded 2013 ACIP influenza vaccination recommendation statement will be published in MMWR Recommendations and Reports prior to the start of the 2013-2014 influenza season. Providers should consult the expanded 2013 ACIP influenza vaccination statement when available for complete and updated information.
Note on Influenza Vaccine Abbreviations
This document includes revised abbreviations to refer to currently available influenza vaccines (also available at ACIP Abbreviations for Vaccines):
The abbreviation TIV (Trivalent Influenza Vaccine, previously used for inactivated influenza vaccines) has been replaced with the abbreviation IIV (Inactivated Influenza Vaccine). For 2013-2014, IIVs as a class will include:
egg-based and cell culture-based trivalent inactivated influenza vaccine (IIV3); and
egg-based quadrivalent inactivated influenza vaccine (IIV4).
RIV refers to recombinant hemagglutinin influenza vaccine, which will be available as a trivalent formulation (RIV3) for 2013-2014.
LAIV refers to live, attenuated influenza vaccine, which will be available as a quadrivalent formulation (LAIV4) for 2013-2014.
LAIV, IIV, and RIV denote vaccine categories; numeric suffix specifies the number of influenza virus antigens contained in the vaccine.
Where necessary to refer specifically to cell culture-based vaccine, the prefix ?cc? is used (e.g., ?ccIIV3?)
Vaccine Recommendations
Routine annual influenza vaccination is recommended for all persons aged 6 months and older. Immunization providers should consult Food and Drug Administration-approved prescribing information for 2013-2014 influenza vaccines and the 2013-2014 ACIP influenza recommendation statement (when available) for the most updated information concerning indications, contraindications, and precautions.
Top
Available Influenza Vaccine Products for 2013-2014
Influenza vaccine products that are currently licensed and expected to be available for the 2013-2014 season and their approved age indications are summarized in Table 1. Information presented is current as of this writing. Any changes in product availability or other information will be reflected in the updated Table included in the upcoming Prevention and Control of Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2013.
Table 1 lists four recently licensed influenza vaccines that are anticipated to be available during the 2013-2014 influenza season. These vaccines are acceptable alternatives to other licensed products listed in Table 1, within specified indications. For persons for whom more than one type of vaccine is appropriate and available, ACIP does not express a preference for use of any one influenza vaccine product over another.
Live, attenuated influenza vaccine, quadrivalent (LAIV4; FluMist? Quadrivalent, MedImmune) [1];
Inactivated influenza vaccine, quadrivalent (IIV4; Fluarix? Quadrivalent, GlaxoSmithKline) [2];
Cell culture-based trivalent inactivated influenza vaccine (ccIIV3; Flucelvax?, Novartis) [3];
Recombinant hemagglutinin influenza vaccine (RIV3; FluBlok?, Protein Sciences) [4].
..
http://www.cdc.gov/flu/professionals/acip/2013-interim-recommendations.htm
This document summarizes recommendations for the use of influenza vaccines approved on February 21, 2013 by the Advisory Committee on Immunization Practices (ACIP). An expanded 2013 ACIP influenza vaccination recommendation statement will be published in MMWR Recommendations and Reports prior to the start of the 2013-2014 influenza season. Providers should consult the expanded 2013 ACIP influenza vaccination statement when available for complete and updated information.
Note on Influenza Vaccine Abbreviations
This document includes revised abbreviations to refer to currently available influenza vaccines (also available at ACIP Abbreviations for Vaccines):
The abbreviation TIV (Trivalent Influenza Vaccine, previously used for inactivated influenza vaccines) has been replaced with the abbreviation IIV (Inactivated Influenza Vaccine). For 2013-2014, IIVs as a class will include:
egg-based and cell culture-based trivalent inactivated influenza vaccine (IIV3); and
egg-based quadrivalent inactivated influenza vaccine (IIV4).
RIV refers to recombinant hemagglutinin influenza vaccine, which will be available as a trivalent formulation (RIV3) for 2013-2014.
LAIV refers to live, attenuated influenza vaccine, which will be available as a quadrivalent formulation (LAIV4) for 2013-2014.
LAIV, IIV, and RIV denote vaccine categories; numeric suffix specifies the number of influenza virus antigens contained in the vaccine.
Where necessary to refer specifically to cell culture-based vaccine, the prefix ?cc? is used (e.g., ?ccIIV3?)
Vaccine Recommendations
Routine annual influenza vaccination is recommended for all persons aged 6 months and older. Immunization providers should consult Food and Drug Administration-approved prescribing information for 2013-2014 influenza vaccines and the 2013-2014 ACIP influenza recommendation statement (when available) for the most updated information concerning indications, contraindications, and precautions.
Top
Available Influenza Vaccine Products for 2013-2014
Influenza vaccine products that are currently licensed and expected to be available for the 2013-2014 season and their approved age indications are summarized in Table 1. Information presented is current as of this writing. Any changes in product availability or other information will be reflected in the updated Table included in the upcoming Prevention and Control of Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2013.
Table 1 lists four recently licensed influenza vaccines that are anticipated to be available during the 2013-2014 influenza season. These vaccines are acceptable alternatives to other licensed products listed in Table 1, within specified indications. For persons for whom more than one type of vaccine is appropriate and available, ACIP does not express a preference for use of any one influenza vaccine product over another.
Live, attenuated influenza vaccine, quadrivalent (LAIV4; FluMist? Quadrivalent, MedImmune) [1];
Inactivated influenza vaccine, quadrivalent (IIV4; Fluarix? Quadrivalent, GlaxoSmithKline) [2];
Cell culture-based trivalent inactivated influenza vaccine (ccIIV3; Flucelvax?, Novartis) [3];
Recombinant hemagglutinin influenza vaccine (RIV3; FluBlok?, Protein Sciences) [4].
..
http://www.cdc.gov/flu/professionals/acip/2013-interim-recommendations.htm